SEATTLE, May 31, 2023 ~ Seal Rock Therapeutics, Inc., a clinical stage company developing first-in-class and best-in-class kinase inhibitors, has entered into an out-licensing agreement with GENFIT (Nasdaq and Euronext: GNFT) for the development of an injectable formulation of SRT-015 for acute liver disease, including Acute-on-Chronic Liver Failure (ACLF).

Under the agreement, Seal Rock Therapeutics is eligible for payments up to €100 million, including regulatory, clinical, and commercial milestone payments, plus tiered royalties.

SRT-015 is a highly optimized, second generation, liver-selective inhibitor of Apoptosis Signal-reducing Kinase 1 (ASK1). It is being developed by Seal Rock Therapeutics in an oral formulation as a treatment for severe acute alcoholic hepatitis as well as orphan liver diseases and NASH.

More on S For Story

• San Diego Author Debuts Thrilling Time-Travel Novel
• Orlando 9-Year-Old Publishes Original Sequel to The Wonderful Wizard of Oz
• Inspiring memoir about growing up well with good support & guidance
• Historical Fantasy 'Keeper of the Hollow' Weaves Faith, Mystery, and Mountain Magic
• Fairmint Introduces First Fully Onchain and Open Cap Table Infrastructure

Neil McDonnell, CEO of Seal Rock Therapeutics expressed his excitement about the licensing deal with GENFIT saying that it will accelerate the development of an injectable formulation of their second generation ASK1 inhibitor SRT-015 for ACLF which is a liver disease with high unmet need. He also added that they remain focused on initiating a Phase 2a trial of oral SRT-015 for severe alcoholic hepatitis and will continue development of their first in class LRRK2/ASK1 dual kinase inhibitors for Parkinson's Disease and ALS.

Pascal Prigent, CEO of GENFIT said that considering its liver centric activity and potential multi organ benefits along with the breadth of evidence supporting further development in ACLF they strongly believe in the potential of SRT-015. He also expressed his pleasure at having this opportunity to develop a new injectable formulation of SRT-015 for Acute on Chronic Liver Failure (ACLF).

---

Show All News | Report Violation